Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether radiation treatment directed at liver
metastases can be safely added to standard of care treatment for extensive stage small cell
lung cancer (ES-SCLC). The current standard treatment for people who have ES-SCLC is
chemotherapy including drugs called carboplatin and etoposide, that is combined with a type
of immunotherapy called atezolizumab. However, patients with liver involvement of their
ES-SCLC don't respond as well to this treatment. The study aims to answer whether adding
radiation directed at liver metastases can improve responses to standard chemo-immunotherapy
in this patient population. All study participants will get the same study intervention,
which will be chemo-immunotherapy and radiation therapy.